Bengaluru, May 15 – In a breakthrough for the pharmaceutical industry, Bengaluru-based Contract Research, Development & Manufacturing Organisation (CRDMO) Steerlife has unveiled a cutting-edge technology that eliminates harmful organic solvents in drug manufacturing.
Indu Bhushan, CEO and director at Steerlife, the life sciences division of Steer World, made the announcement, describing the innovation as a major leap forward in pharmaceutical science.
Proprietary Melt Fusion Technology at the Core
“At the heart of this innovation is our proprietary solvent-free melt fusion technology,” said Bhushan. “This continuous processing system replaces traditional methods that rely on toxic solvents, offering a cleaner and safer approach to drug development. It is designed to precisely handle high-potency and hard-to-develop molecules, improving formulation efficiency, safety, and scalability.”Shift from Batch to Continuous Processing
From Steerlife’s marketing team, Arjun Suresh highlighted the efficiency gains from this new approach. “Traditional drug development relies on batch processing, a laborious step-by-step method. In contrast, Steerlife’s continuous process technology reduces the number of steps from eight or nine to just three or four, significantly accelerating the workflow,” he explained.Innovation for Complex and Potent Drugs
As a next-generation CRDMO, Steerlife supports the development of complex and potent drugs, including New Chemical Entities (NCEs), hormone therapies, orphan drugs, complex generics (ANDAs), and 505(b)(2) products. The company aims to empower global pharmaceutical companies by addressing development and manufacturing challenges through process-driven innovation.“Potent drug development is not just about regulatory compliance; it’s about precision, care, and innovation,” said Bhushan. “Our solvent-free, continuous manufacturing platform combines all these aspects to deliver faster, cleaner, and scalable solutions for the world’s most demanding therapies.”
Commercial Rollout from 2026
Steerlife has already begun developing several key drug products using this new technology, with market launches planned from 2026 onwards. This move signals the company’s transition from research and development to commercial application.With this innovation, Steerlife positions itself at the forefront of sustainable and advanced pharmaceutical manufacturing, redefining industry standards and contributing to safer drug development worldwide.